Showing results (231-240 of 241) with videos related to
Sort By:
Pageof 25
Clinical Pharmacology and Therapeutics|July 1, 1990
Dose-response effects of pentoxifylline on erythrocyte filterability: clinical and animal model studiesJ L Ambrus, J M Anain, S M Anain, et al.Journal of Immunology (Baltimore, Md. : 1950)|October 4, 2006
Development of autoimmunity in IL-14alpha-transgenic miceLong Shen, Chongjie Zhang, Tao Wang, et al.Blood|January 1, 1988
Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxinsF M Uckun, W Jaszcz, J L Ambrus, et al.Clinical and Translational Medicine|April 3, 2023
Targeting alarmin release reverses Sjogren's syndrome phenotype by revitalizing Ca2+ signallingYuyang Sun, Viviane Nascimento Da Conceicao, Arun Chauhan, et al.Blood|February 22, 2007
Development of a murine model for blastoid variant mantle-cell lymphomaRichard J Ford, Long Shen, Yen Chiu Lin-Lee, et al.Archives of Internal Medicine|November 1, 1989
Association between active Wegener's granulomatosis and anticytoplasmic antibodiesJ W Tervaert, F J van der Woude, A S Fauci, et al.Rheumatology (Oxford, England)|March 26, 2025
Evaluating the therapeutic potential of tofacitinib in Sjögren's disease: a comprehensive clinical and immunological assessmentQinghong Liu, Yuqing Zeng, Xiaoyan Xing, et al.JAMA|April 25, 1977
Prevention of hyaline membrane disease with plasminogen. A cooperative studyC M Ambrus, T S Choi, E Cunnanan, et al.Seminars in Thrombosis and Hemostasis|July 1, 1975
Studies on the prevention of respiratory distress syndrome of infants due to hyaline membrane disease with plasminogenC M Ambrus, T S Choi, D H Weintraub, et al.JAMA Network Open|November 10, 2022
Efficacy and Safety of Low-Dose Interleukin 2 for Primary Sjögren Syndrome: A Randomized Clinical TrialJing He, Jiali Chen, Miao Miao, et al.Pageof 25